Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results

SIMPLE SUMMARY: Survival outcomes with standard cytotoxic chemotherapy are poor, and most patients with ovarian cancer will die with platinum-resistant disease. This may reflect the existence of drug-resistant ovarian cancer stem cells. Cantrixil is a novel third-generation benzopyran molecule, with...

Descripción completa

Detalles Bibliográficos
Autores principales: Coward, Jermaine I., Barve, Minal A., Kichenadasse, Ganessan, Moore, Kathleen N., Harnett, Paul R., Berg, Daniel, Garner, James S., Dizon, Don S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268018/
https://www.ncbi.nlm.nih.gov/pubmed/34206826
http://dx.doi.org/10.3390/cancers13133196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268018/
https://www.ncbi.nlm.nih.gov/pubmed/34206826
http://dx.doi.org/10.3390/cancers13133196

Ejemplares similares